ABSTRACT: HIV-1 infection is characterized by multiple neurological syndromes occuring at all stages of infection. HIV-1-associated dementia, however, is the most devastating CNS consequence of AIDS because of its poor prognosis and functional impairment. A clinical triad of progressive cognitive decline, motor dysfunction, and behavioural abnormalities typifies this subcortical dementia which eventually affects 15 to 20% of AIDS patients. Neuroimaging, CSF studies and neuropsychological testing are frequently required in diagnosing HIV-associated dementia, to exclude other conditions including psychiatric illnesses, opportunistic diseases and systemic disorders. The pathogenesis of HIV dementia is uncertain and there is evidence that multiple mechanisms of neurological injury occur. These mechanisms include: the role of neurovirulent strains of HIV; the potential neurotoxicity of HIV gp!20, nitric oxide and quinolinic acid; immunologically mediated CNS injury through the action of cytokines and arachidonic acid metabolites; and altered bloodbrain barrier permeability. A collective approach involving clinical studies, in vitro assays and animal models will provide greater insight into the pathogenesis and the rational development of therapy for HIV dementia. RESUME: La demence associee a I'infection par le VIH-1: manifestations cliniques et pathogenese. L'infection par le VIH-1 est caracterisee par des syndromes neurologiques varies survenant a tous les stages de l'infection. Cependant, la demence associee au VIH-1 (DVIH) est la consequence la plus devastatrice du SIDA au niveau du SNC a cause de son pronostic sombre et de ses repercussions fonctionnelles. La triade clinique constitute d'un ddclin cognitif progressif, de dysfonction motrice et d'anomalies du comportement est typique de cette demence sous-corticale qui touche de 15 a 20% des patients atteints du SIDA au cours de leur maladie. L'imagerie du SNC, I'examen du LCR et les epreuves neuropsychologiques sont souvent requises pour poser un diagnostic de DVIH afin d'exclure une maladie psychiatrique, une infection opportuniste ou une maladie syst6mique. La pathogenese de la DVIH est mal connue et, selon certaines donnees, plusieurs mecanismes sont en cause, incluant le role de souches neurovirulentes du VIH, la neurotoxicite possible de la gpl20 du VIH, de I'oxyde nitrique et de l'acide quinolinique, l'atteinte du SNC a mediation immunitaire par les cytokines et les metabolites de l'acide arachidonique et une alteration de la permeabilite de la barriere hemato-encephalique. Une approche globale impliquant des etudes cliniques, des dtudes in vitro et des modeles animaux permettra d'elucider sa pathogenese et de deVelopper un traitement de la DVIH.
Figure I: HIV-1 is associated with neurological diseases at all stages of infection and at all levels of the nervous system (reprinted by permission).
 14 
CLINICAL FEATURES
HIV dementia (HIVD) 16 which has also been termed HIV-1 associated dementia complex 17 or AIDS dementia complex 18 is characterized by a clinical triad of cognitive impairment, motor dysfunction and behavioural abnormalities. 1619 The onset of HIVD is the first AIDS-defining illness in 3% of HIV-infected patients, but most of these patients also have CD4 levels of 200 cells/mm 3 or less. 20 It is noteworthy that cognitive impairment in the pre-symptomatic stages of HIV-1 infection is not widespread or a requisite feature of HIV infection, 21 " 23 contrary to early reports of widespread neuropsychological deficits in pre-AIDS patients. Eventually, HIVD affects 15 -20% of all patients with AIDS and is associated with a worsened prognosis with a mean survival time of 7 months. 24 HIVD is a subcortical dementia presenting with memory loss, depressive symptoms, apathy, withdrawal from routine activities, and occasionally psychosis. 1619 In the early stages of dementia, it is often difficult to distinguish this syndrome from psychiatric illness or opportunistic infections of the CNS. The clinical diagnosis of HIVD thus may require extensive history taking from family members or friends, psychiatric and/or neuropsychological evaluations, CSF and radiological studies. The physical examination in patients with HIVD is notable for psychomotor slowing, hyperreflexia, hypertonia, ataxia, release signs, impaired rapid movements and an accompanying myelopathy. Diagnostic criteria recommended by the American Academy of Neurology 17 for HIV dementia include: 1) HIV-1 seropositivity; 2) history of progressive cognitive and behavioral decline; 3) neurological and/or neuropsychological evaluation consistent with decline from premorbid baseline; and 4) CNS opportunistic processes excluded by CT or MR imaging and CSF analysis. The syndrome demonstrates a marked diversity in its rate of advancement, as shown in Figure 2 , but the factors that determine this variability in the disease course are uncertain. Cognitive slowing and ataxia may progress to complete mutism and paraparesis with fecal and urinary incontinence. The severity of cognitive and motor impairment can be staged using Memorial Sloan-Kettering (MSK) scale which assesses a patient's functional impairment. 25 The MSK scale ranges from mild dementia or minimal cognitive and motor deficits (MSK = 1) to severe dementia or end-stage vegetative state (MSK = 4).
Neuropsychology
HIV dementia has a characteristic neuropsychological profile with progressive decline in performance in, at least, two areas LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES including motor speed, nonverbal memory and frontal lobe tasks. 26 Because it is essential to diagnose an altered mental status in AIDS patients as early as possible and neuropsychological testing is not universally available, a brief quantitative diagnostic test was developed, the HIV Dementia Scale (HDS), 27 to be used in conjunction with other diagnostic tests. This scale tests specific abilities including timed motor tasks, frontal lobe functions and memory that are impaired early in HIV infection ( Figure 3 ). The HDS is easily administered at the bedside with superior sensitivities and specificities to other short mental status assessments such as the Minimental Status Examination.
28
- 29 This test may also be of value in following patients' cognitive status over time and response to therapy.
Laboratory Investigations
Additional diagnostic tests include CSF and radiological studies to rule out other causes of altered mental status. However nonspecific abnormalities may occur in some patients with HIV dementia including elevated p24 levels, total protein (60%), IgG fraction (80%), oligoclonal bands (35%) and a lymphocytosis with CD4/CD8-positive cell ratios in CSF that mirror those in peripheral blood. 
Differential Diagnosis
The differential diagnosis for HIVD includes psychiatric illnesses, CNS opportunistic infections and neoplasms, and systemic disorders. Depression and psychosis can be mistakenly diagnosed in patients with HIVD and thus psychiatric and neuropsychological evaluations are often helpful. CNS opportunistic and neoplastic diseases to be ruled out include cerebral toxoplasmosis, cryptococcal meningitis, progressive multifocal leucoencephalopathy, CNS lymphoma, and cytomegalovirus encephalitis (CMVE). Radiological and CSF analyses show specific changes that identify the former four conditions, however CMVE may be more difficult to diagnose. A rapid downhill course, prominent systemic CMV infection, 27 hyponatremia, CMV genome detection in CSF by the polymerase chain reaction (PCR), and characteristic periventricular lesions on CT or MRI scans help to distinguish CMVE from HIVD. 35 Other common systemic complicating conditions such as hypoxia, intoxicants and renal or hepatic failure require investigation and exclusion before the diagnosis of HIVD may be made.
Neuropathology
Pathological features of HIV dementia observed by histopathological methods are striking for the lack of correlation between the severity of d e m e n t i a and the i n f l a m m a t o r y p a t h o l o g i c a l changes. 18 2. History of progressive subacute mental decline: apathy, memory loss, and slowed cognition.
3. Physical findings include slowed limb and eye movements, hyperreflexia, hypertonia, release signs and an HDS score of < 10.
4. Neuropsychological testing demonstrates worsening performance in at least two areas including frontal lobe tasks, motor speed, and nonverbal memory.
5. CSF studies show elevated p24, IgG, and protein levels and the absence of other infections, i.e., cryptococcus and syphilis.
6. Cranial imaging reveals cerebral atrophy and white matter abnormalities including hyperintensities on MRI and hypodensities on CT; exclusion of opportunistic processes.
7. Exclusion of major psychiatric and metabolic disorders, and substance abuse.
tion to neuronal loss, more sensitive morphological techniques have indicated that a loss of synaptic contacts and vacuolar changes in neurons in both the deep grey matter and cortex occur in patients dying with AIDS. 5 4 5 6 There is a paucity of lymphocytes found in the brains of patients dying with AIDS unlike the CSF in which there is a lymphocytosis; 30 thus, equating the CSF cell profile with the cell types and degree of inflammation found in the brain in patients with AIDS can be very misleading.
HIV Detection in Brain
HIV antigens and viral genome can be detected in the brains of AIDS patients, 45 " 47 primarily in the deep grey matter and white matter. 48 A definitive correlation between viral burden in the brain and the severity of clinical neurological disease has not yet been shown. In fact, a striking dichotomy exists between the small number of HIV-infected cells and the severity of the clinical phenotype. 49 The majority of cells infected in the CNS are microglia and perivascular macrophages 45 syndrome but the observation that HIVD is, in part, reversible provides optimism in considering therapeutic interventions.
PATHOGENESIS
In attempting to understand the mechanisms underlying the development of CNS disease associated with HIV infection, experimental approaches in the fields of neurobiology, immunology, molecular biology, and virology have been employed. Consequently, numerous hypotheses with supporting data from studies of both animal retrovirus models and humans in addition to in vitro cell culture techniques to explain the pathogenesis of HIVD have emerged over the past ten years. These hypotheses include roles for potential host and viral neurotoxic molecules, 61, 62 immunological molecules that are damaging to the CNS 63, 64 and the role of distinct viral strains in the development of HIV-related CNS disease. 6569 Each of these strategies will be reviewed but it is prudent to bear in mind that there are few correlative data between the results of in vitro assays and in vivo findings to date.
It is widely assumed but not documented that HIV gains access to the brain through infected blood-derived macrophages or monocytes that traverse blood-brain barrier whereupon susceptible adjacent cells (microglia and astrocytes) become infected. This proposed route of infection has been termed the Trojan Horse hypothesis 7 " and is supported by data indicating that many of perivascular cells observed in the brains of AIDS patients are HIVinfected macrophages. 45 Cellular entry by HIV into blood-derived macrophages and T cells is dependent on the cell surface molecule, CD4, which acts as a receptor for HIV. 71 But in the CNS, the picture is more complicated because in addition to CD4, other HIV receptors have been identified including the molecule, galactocerebroside, 72 and putative receptors on astrocytes 73 and endothelial cells.
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HIV Strain Diversity As with other viruses, the envelope protein of HIV participates in cellular entry and influences its tropism or which cells are infected. HIV cell tropism is dependent on specific sequences within the V3 region within the envelope.
75
- 76 In the few patients from whom brain-derived HIV envelope sequences including the V3 region were obtained, a striking homogeneity in viral sequences was observed. 6567 This finding is in contrast to HIV blood-derived envelope sequences and strains which may vary widely depending on the stage of disease and the individual host. 5 The brain-derived sequences of HIV resemble macrophage-tropic HIV strains and infection by live brain-derived isolates is restricted to macrophages in vitro. 16 " 1 * Thus, it is not surprising that principal cell infected in the CNS is the microglia which is of macrophage lineage. Macrophage tropism is, therefore, a necessary feature of an HIV strain to infect the CNS and subsequently cause disease.
Different retroviruses show a marked variation in their ability to infect the CNS (neurotropism) and cause neurological disease (neurovirulence) in animal models. 7982 Some animal lentiviruses such as simian immunodeficiency virus and Visna/Maedi are characterised by neurovirulent strains.
-
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- 84 To address the question of whether there are distinct sequences of HIV that are associated with neurovirulence, i.e., the ability to cause dementia, a study was performed comparing HIV envelope sequences from HIVD and non-demented AIDS patients. 85 HIV proviral DNA was derived from autopsied brains of HIVD and control non-demented (ND) AIDS patients who were closely followed in the NeuroAIDS clinic premortem at the Johns Hopkins Hospital. The HIVD and ND groups were matched for age, CD4 level, and antiretroviral therapy. Sequence analysis of the V3 and flanking regions of HIV envelope was performed. The brain-derived HIV sequences from all patients regardless of group resembled previously reported macrophagetropic strains of HIV (Figure 4 ). Two positions, 305 and 329, in the 143 amino acid fragment encompassing the V3 region showed significant diversity between the two clinical groups ( Figure 5 ). In addition, sequences derived from individuals with HIVD exhibited multiple residues at which unique amino acids relative to the nondemented group were identified. The unique amino acids were more frequently observed in the more severely demented patients. These results indicate that macrophage-tropic strains occur in the brains of all AIDS patients but, in addition, there are distinct HIV sequences related to the clinical development of HIVD. Whether these sequence differences are directly involved in the pathogenesis of HIVD or merely linked to other neurovirulent genes is unknown, however, it is of interest that peptides made from the V3 and flanking regions have been shown to be not neurotoxic in vitro although peptides derived from HIV strains associated with HIVD have not yet been evaluated. 86 Tropism studies of recombinant infectious HIV clones bearing the brain-derived V3 regions from patients with and without HIVD revealed that these clones infected only macrophages and microglia, suggesting that HIV macrophagetropism is an essential step in the development of neurovirulence. 87 Further sequence analysis of other regions of the HIV genome and the reconstruction of HIV recombinant clones to be tested in vitro using different genomic regions of HIV may elucidate viral genetic determinants participating in the pathogenesis of HIVD.
Figure 4: Comparison of the homology of V3 sequences of brain-derived clones and previously reported blood-derived clones and isolates of known tropism with the macrophage tropic consensus sequence. Each dot represents a different clone. Regardless of clinical group (HIVD or ND). brainderived isolates were similar to blood-derived macrophage-tropic isolates and differed significantly from blood-derived nonmacrophage-tropic isolates (reprinted by permission).
Neurotoxicity
Potential host and viral neurotoxic molecules have been identified in association with HIV infection. 8889 The HIV gpl20 envelope protein has been shown to the neurotoxic in different in vitro and in vivo systems. 6190 The means of neuronal injury and death may be direct or indirect although it appears to be a excititoxic mechanism, being both calcium-dependent and mediated by glutamate (NMDA) receptors. 88 gpl20 neurotoxicity is reduced by both calcium channel blockers and glutamate receptor blockers which has led to a clinical trial in which different calcium channel blockers are being tested therapeutically in patients with HIVD. Other neurotoxic agents have been implicated in the pathogenesis of HIVD including quinolinic acid which is tryptophan-derived and has been shown to be elevated in the CSF of patients with HIVD 62 and nitric oxide which appears enhance gpl20 neurotoxicity. 91 Guilian et al. have identified a small molecule (< 5000 kD) which has been shown to damage neurons in vitro and is secreted by HIV-infected macrophages and/or macrophages treated with gpl20 peptide. 86 An indirect mechanism of neurotoxicity seems most plausible in light of the small number of HIV infected cells in the CNS.
Neuroimmunolgy
Immunological activation is a feature of HIV infection both within and outside the CNS. 8892 Astrocytes and microglia appear activated early in infection 39 - 93 and different immunological molecules produced by these cell types including cytokines and arachidonic acid metabolites show increased expression in vivo and in vitro in association with HIV infection. have been shown to be associated with HIV infection in glial cultures.
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- 97 To examine the influence of host genetic diversity on the susceptibility to immunological activation in the pathogenesis of HIVD, studies of HLA antigen expression in patients with and without HIVD are underway.
Blood Brain Barrier Alteration
The consequences of immunological activitation within the CNS are diverse. TNF-alpha is known to induce expression of MHC Class I and II expression within the CNS, enhance viral replication and is toxic in glial cultures. 88 -98 In addition, TNF and other cytokines may alter the permeability of the blood-brain barrier (BBB) as observed in other CNS inflammatory diseases. 99101 Early reports suggested that the blood brain barrier was more permeable in patients with AIDS. 102104 To test the hypothesis that the BBB was more permeable in patients with HIVD compared to HIV seropostive and seronegative patients, a study of age and autopsied-time matched seronegative, preAIDS, and AIDS patients with and without HIVD was performed. 93 BBB integrity was analysed by the extrusion of serum proteins into the brain parenchyma. The results of this study indicated that increased BBB permeability occurred in all patients with HIVD but rarely in AIDS patients without HIVD or seronegative controls except in those individuals with some other inflammatory neurological disease (Figure 7 ). Increased BBB permeability was significantly associated with diffuse myelin pallor on pathological samples and increased signal intensity in white matter of T, weighted MRI scans in patients with HIVD. In patients with HIVD, serum proteins were detected in cortical neurons which exhibited dysmorphic appearances suggesting that these neurons were injured or dying. The mechanism underlying altered bloodbrain barrier permeability is unclear although other groups have identified abnormalities in cerebral endothelia morphology in patients with HIVD. 105 To examine the expression of different cell adhesion molecules on cerebral endothelia, studies of ICAM-1 and VCAM-1 were performed in the same group of patients studied in the BBB permeability analysis. These molecules were chosen because they are known to be induced by cytokines such as TNFalpha, and bind monocytes; thus they may facilitate the CNS entry of potentially HIV-infected macrophages/monocytes. 106 Detection of ICAM-1 on cerebral endothelium by immunocytochemistry was significantly greater in AIDS patients compared to seronegative controls although there were no differences between demented and nondemented AIDS patients. Surprisingly, VCAM-1 was identified primarily on cells within microglial nodules in patients with AIDS and rarely on cerebral endothelia. 107 These studies suggest that the expression of certain cell adhesion molecules is enhanced in the CNS of AIDS patients which may be an initial step in the pertubation of the blood brain barrier's permeability although other groups of adhesion molecules such as the cadherins may also be involved. It is clear that immunological factors participate in the development of HIV related CNS disease with significant consequences. However, many questions remain to be answered including the specific mechanism by which different immune molecules cause neurological injury, the extent and mechanisms of immune surveillance of HIV infected cells within the CNS.
Animal Models
The use of animal models in testing many of the hypotheses presented above has become increasingly important. A variety of models have become popularized over the past decade. SIV infection of macaques and FIV infection of cats, both of which are lentiviruses, produce clinical and pathological neurologic disease. 80 ' 84 ' 08 Severe combined immune deficient mice (SCID) infected intracranially with HIV display pathological features similar to HIV encephalitis. 109 Transgenic mice have also been used to study the effects of expression of different HIV genes within the CNS." 0 1 " Of particular interest is the transgenic model in which HIV gpl20 expressed under the control of a GFAP promoter.
1 " In this model, neuronal changes similar to those seen in AIDS patients have been observed although behavioral correlations have not yet been published.
Future Questions
HIV-related neurological disease has attracted interest from the time of the onset of the pandemic because of its high prevalence among patients with AIDS and the ensuing clues to the development of other neurological diseases. Much of the attention has been directed towards studying the clinical phenomenology and possible pathogenic mechanisms to establish a rational approach to therapy. However, important clinical issues yet to be addressed include the role of drug (AZT) resistance in CNS disease progression, epidemiological analysis of HIV-1 and HIV-2-related neurological diseases in other geographic regions affected by HIV, i.e., Africa and Asia, identification of more specific risk factors and diagnostic tools, and the development and testing of new therapies. Large steps have been made in understanding the pathogenesis of HIVD especially in the areas of immunology and neurotoxicity but a comprehensive understanding is still lacking especially in the area of pediatric HIV-associated neurological disease, likely because of the multiple mechanisms are involved. Many questions remain unanswered concerning the role of CNS viral load in relation to clinical disease, specific mechanisms underlying viral protein-and cytokine-mediated neurologic disease, the existence of other CNS receptors for HIV, host resistance genes, and complementary viruses involved in the pathogenesis of CNS disease as have been observed in animal retroviral diseases. 8 1 " 2 " 4 A combined approach in the future using in vitro assays correlated with clinical findings, animal models and clinical-pathological studies will provide more insights into the pathogenesis of HIVD and the sound development of new treatments for HIVD. In addition, analysis of viral and host interactions within a comparatively closed system, such as the brain, may provide useful perspicacity into HIV-associated disease in other organ systems. This may be helpful in discerning the interaction between the evolution of HIV virulence and the impact of immunological pressure on the progression of disease. Furthermore, studies of a rapidly mutating pathogen such as HIV in relation to CNS disease may permit a broader understanding of the rules governing neurovirulence that could be applied to the treatment of other CNS viruses such as HTLV-1, Japanese B and Herpes simplex encephalitides.
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